FKBP35 secures ribosome homeostasis inPlasmodium falciparum

Abstract

ABSTRACTPlasmodium falciparumaccounts for the majority of over 600’000 malaria-associated deaths annually. Parasites resistant to nearly all antimalarials have emerged and the need for drugs with alternative modes of action is thus undoubted. The FK506-binding proteinPfFKBP35 has gained attention as a promising drug target due to its high affinity to the macrolide compound FK506 (tacrolimus). Whilst there is considerable interest in targetingPfFKBP35 with small molecules, a genetic validation of this factor as a drug target is missing and its function in parasite biology remains elusive. Here, we show that limitingPfFKBP35 levels are lethal toP. falciparumand result in a delayed-death phenotype that is characterized by defective ribosome homeostasis and stalled protein translation. We furthermore show that FK506, unlike the role of this drug in model organisms, exerts its anti-proliferative activity in aPfFKBP35-independent manner and, using cellular thermal shift assays, we identify FK506-targets beyondPfFKBP35. In addition to revealing first insights into the function ofPfFKBP35, our results show that FKBP-binding drugs can adopt non-canonical modes of action – with major implications for the development of FK506-derived molecules active againstPlasmodiumparasites and other eukaryotic pathogens.